Fragment-based screening of the bromodomain of ATAD2

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9687-9692

  Harner, Mary J ^a   Chauder, Brian A ^a   Phan, Jason ^a   Fesik, Stephen W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AAA DOMAIN CONTAINING PROTEIN 2; AAA DOMAIN CONTAINING PROTEIN 2 BROMODOMAIN INHIBITOR; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; BROMODOMAIN INHIBITOR; IMIDAZOLE DERIVATIVE; NUCLEAR PROTEIN; OXADIAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ATAD2 PROTEIN, HUMAN; DNA BINDING PROTEIN; LIGAND;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG IDENTIFICATION; DRUG SCREENING; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; NITROGEN NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY CRYSTALLOGRAPHY; BINDING SITE; CHEMISTRY; CONFORMATION; HUMAN; KINETICS; MEDICINAL CHEMISTRY; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; BINDING SITES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; HUMANS; KINETICS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

EID: 84913558442     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501035j     Document Type: Article

References (19)

1. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation Nature Rev. Drug Discovery 2014, 13, 337-356
2. PFI-3: Selective chemical probe for SMARCA bromodomains; Structural Genomics Consortium: Toronto; http://www.thesgc.org/chemical-probes/PFI-3.
3. Ferguson, F. M.; Fedorov, O.; Chaikuad, A.; Philpott, M.; Muniz, J. R.; Felletar, I.; von Delft, F.; Heightman, T.; Knapp, S.; Abell, C.; Ciulli, A. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain J. Med. Chem. 2013, 56, 10183-10187
4. Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Virolle, V.; Barbry, P.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers Oncogene 2010, 29, 5171-5181
5. Hsia, E. Y.; Kalashnikova, E. V.; Revenko, A. S.; Zou, J. X.; Borowsky, A. D.; Chen, H. W. Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer Mol. Cancer Res. 2010, 8, 183-193
6. Kalashnikova, E. V.; Revenko, A. S.; Gemo, A. T.; Andrews, N. P.; Tepper, C. G.; Zou, J. X.; Cardiff, R. D.; Borowsky, A. D.; Chen, H. W. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2 Cancer Res. 2010, 70, 9402-9412
7. Revenko, A. S.; Kalashnikova, E. V.; Gemo, A. T.; Zou, J. X.; Chen, H. W. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark Mol. Cell. Biol. 2010, 30, 5260-5272
8. Yang, J.; Huang, J.; Luo, L.; Chen, Z.; Guo, Y.; Guo, L. Significance of PRO2000/ANCCA expression, a novel proliferation-associated protein in hepatocellular carcinoma Cancer Cell Int. 2014, 14, 33
9. Zou, J. X.; Guo, L.; Revenko, A. S.; Tepper, C. G.; Gemo, A. T.; Kung, H. J.; Chen, H. W. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer Cancer Res. 2009, 69, 3339-3346
10. Zou, J. X.; Revenko, A. S.; Li, L. B.; Gemo, A. T.; Chen, H. W. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 18067-18072
11. Ciro, M.; Prosperini, E.; Quarto, M.; Grazini, U.; Walfridsson, J.; McBlane, F.; Nucifero, P.; Pacchiana, G.; Capra, M.; Christensen, J.; Helin, K. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors Cancer Res. 2009, 69, 8491-8498
12. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites J. Med. Chem. 2012, 55, 7346-7359
13. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
14. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins Science 1997, 278, 497-499
15. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274, 1531-1534
16. Harner, M. J.; Frank, A. O.; Fesik, S. W. Fragment-based drug discovery using NMR spectroscopy J. Biomol. NMR 2013, 56, 65-75
17. Chaikuad, A.; Petros, A.; Fedorov, O.; Xu, J.; Knapp, S. Structure-based approaches towards indentification of fragments for the low-druggability ATAD2 bromodomain. MedChemComm 2014, DOI 10.1039/C4MD00237G.
18. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525
19. Ember, S. W.; Zhu, J. Y.; Olesen, S. H.; Martin, M. P.; Becker, A.; Berndt, N.; Georg, G. I.; Schonbrunn, E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 2014, 9, 1160-1171